CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma.
Wang Y, Chen J, Gao Y, Chai KXY, Hong JH, Wang P, Chen J, Yu Z, Liu L, Huang C, Taib NAM, Lim KMH, Guan P, Chan JY, Huang D, Teh BT, Li W, Lim ST, Yu Q, Ong CK, Huang H, Tan J.
Wang Y, et al. Among authors: huang c.
Cancer Lett. 2024 Jun 20:217080. doi: 10.1016/j.canlet.2024.217080. Online ahead of print.
Cancer Lett. 2024.
PMID: 38908542